Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Alpharma

This article was originally published in The Tan Sheet

Executive Summary

Alpharma: Gert Wilhelm Munthe is new president and chief operating officer of the private label manufacturer. Munthe, formerly president and CEO of Oslo, Norway-based NetCom ASA, has been a member of the Alpharma board for four years. He reports to Alpharma Chairman and CEO Einar Sissener and is expected to succeed Sissener when he steps down from the CEO position in 1999; Sissener will continue as chairman of the board. The company's five Strategic Business Unit presidents, as well as the chief financial officer, now report to Munthe. Alpharma recently received tentative FDA approval for its ANDA for ibuprofen oral suspension, comparable to McNeil's Children's Motrin, for which marketing exclusivity expires June 16 ("The Tan Sheet" Jan. 19, In Brief)...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088181

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel